Healthcare is having a complex 2026. GLP-1 drugs are reshaping pharma economics, biotech valuations are swinging on clinical data, and the sector's average risk profile has climbed. In that environment, fundamental strength isn't just nice to have. It's the filter separating resilient businesses from noise.
Three stocks cut through clearly. United Therapeutics (UTHR) holds the highest fundamental health score in the entire Stoxcraft universe of 3,484 stocks. Krystal Biotech (KRYS) combines extraordinary price performance with a strong fundamental base. Eli Lilly (LLY) pairs mega-cap scale with a risk profile that outperforms most of its sector peers.
Healthcare sector score overview this week
The healthcare sector's average fundamental score sits above the universe median, but it's a wide distribution. The gap between the sector's strongest and weakest names has stretched to one of its widest readings in 18 months, driven by diverging revenue trajectories across pharma and biotech.
Here's where the sector stands right now:
- Average fundamental health score: above universe median
- Average performance score: top third across all 11 GICS sectors
- Average risk score: elevated, above universe median
- Stocks with strong upward trend signals: fewer than 20% of the sector
- Dominant analyst signal: Buy, concentrated in large-cap pharma and specialty biotech
The key story isn't the average. It's how far above it the top three names sit.
Current news driving healthcare scores
The GLP-1 obesity drug cycle is the dominant force reshaping healthcare scores in 2026. Global GLP-1 spending is projected to surpass $130B by 2030, pulling capital and analyst attention toward names with established pipelines and defensible revenue streams.
That's lifting performance scores for large-cap pharma and compressing them for smaller biotechs without near-term catalysts. Companies with strong cash flow and clean balance sheets are scoring well. Everyone else is getting repriced.
Top healthcare stocks by Stoxcraft score
Three names stand out when you rank the healthcare sector by combined fundamental strength and performance profile. Here's where each one sits and what's driving the numbers.
United Therapeutics (UTHR): overall rating 4.5 stars
United Therapeutics is the most fundamentally sound stock in the entire Stoxcraft universe right now. Not just in healthcare. In all 3,484 stocks tracked. UTHR is the only name to reach the maximum on fundamental health, powered by an extraordinary free cash flow profile and consistent revenue growth that places it at the very top of its sector.
The performance score sits at 8.7 out of 10, placing UTHR in the top 15% of all tracked stocks across time horizons. The risk profile is moderate for a healthcare name: it earns top-decile returns without the extreme volatility that typically accompanies high-growth biotech names.
Analyst consensus is aligned at Strong Buy. The stock trades below its 52-week high, meaning the setup hasn't been chased. The overall rating is 4.5 stars, the strongest fundamental case in the sector by a significant margin.
Krystal Biotech (KRYS): overall rating 4 stars
Krystal Biotech's score is built on one of the strongest performance records in the sector. Its performance score of 9.8 out of 10 places it in the top 2% of all 3,484 tracked stocks, driven by sustained outperformance across the 1-year and 3-year horizons. That's not short-term noise. It's a compounding story with data behind it.
The fundamental health score of 8.2 sits well above the healthcare sector average, reflecting strong profitability relative to biotech peers. The risk score is elevated, which is expected for a smaller-cap biotech, but the fundamental base keeps the overall rating at 4 stars.
Earnings have consistently beaten expectations. Analyst consensus sits at Buy. The technical picture shows early upward momentum, with all short-term indicators pointing in the same direction.
Eli Lilly (LLY): overall rating 4 stars
Eli Lilly's profile differs from the other two. The fundamental health score of 8.0 ranks LLY in the top 10% of the entire healthcare sector by balance sheet quality and profitability. But the standout factor is risk. LLY's volatility profile sits below 75% of all healthcare stocks tracked, which is unusual for a stock with this level of growth characteristics.
The performance score of 7.6 reflects consistent long-term outperformance versus the S&P 500, though short-term momentum has moderated after a strong multi-year run. Mounjaro and Zepbound have driven a step-change in Lilly's revenue trajectory, with analyst consensus remaining strongly bullish across major research desks.
The overall rating is 4 stars. The entry signal sits at Buy, supported by analyst consensus and a stock that has pulled back from recent highs, creating a more favorable setup than existed 6 months ago.
Stocks to watch in healthcare
Two names outside the top three show score dynamics worth tracking. Novo Nordisk (NVO) has seen its performance score compress after a sharp pullback from its 52-week high, but the fundamental score remains in the top quartile of the sector. A reversal in momentum could push NVO back toward the top three quickly. Pfizer (PFE) presents the opposite picture: a below-average performance score dragged down by post-COVID revenue normalization, but a fundamental floor that keeps the overall rating stable. Both names show a wider-than-usual gap between their score components, which tends to precede a move in one direction or the other.
Why these three healthcare stocks lead the sector in 2026
No other stock across 3,484 names has hit the top of the fundamental health scale. That's not a quirk in the data. It reflects a business that has generated extraordinary free cash flow, sustained revenue growth over five years, and maintained balance sheet discipline while peers have stretched for growth.
UTHR's perfect score is the headline. But the fuller picture is a trio of names with genuinely differentiated profiles. KRYS offers elite performance credentials with higher short-term risk. LLY combines mega-cap scale with surprisingly low volatility and GLP-1 tailwinds still building. Each serves a different investor preference within the same sector thesis: strong fundamentals are the durable edge when everything else is uncertain.
